"Efti - 'a blockbuster in the making' (analyst comment) - peak sales $5.1 billion forecast. (2030)
Current Valuation - average from 3 analysts - $1.15 share.
Highly likely a MA (merger/acquisition) 12-24 months - $2.00 - $3.00 share (this purely my guesstimate)."
If EFTI is the blockbuster drug with 5 billion in sales, then with a PE of 20 IMMP the US share price would be $1500. The ASX price would be $200. This is a once in a lifetime opportunity for all shareholders, Marc and Frederic included.
About 12 years ago on a BBC broadcast Frederic expressed a concern that a merger could result in some of IMM technology being shelved. For example BMS could acquire IMM and keep Efti on the shelf while they promote their antibody relatlimab.
When push comes to shove Marc et al would rather dilute their shares a little to keep IMM independent. And eventually maximize everyone's shares.
I don't IMM management would entertain an offer MA of $3 a share. More than likely they have already turned down offers in this range.
IMM Price at posting:
50.0¢ Sentiment: Buy Disclosure: Held
(20min delay)